Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-5214 monotherapy in MDD
NCT01288079Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Feb 2011
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of dexmecamylamine in major depressive disorder (MDD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Montgomery Asberg Depression Rating Scale Total Score at Week 16. Started Feb 2011; status: terminated.
02
Drugs
dexmecamylamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01288079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01288079.